Acurx Pharmaceuticals, Inc.
ACXP
$0.33
-$0.029-8.08%
| Weiss Ratings | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.37 | |||
| Price History | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -22.44% | |||
| 30-Day Total Return | -51.63% | |||
| 60-Day Total Return | -69.72% | |||
| 90-Day Total Return | -76.26% | |||
| Year to Date Total Return | -60.71% | |||
| 1-Year Total Return | -83.50% | |||
| 2-Year Total Return | -90.38% | |||
| 3-Year Total Return | -90.63% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -89.20% | |||
| 52-Week Low % Change | 2.57% | |||
| Price | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.33 | |||
| 52-Week Low Price | $0.35 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Jul 18, 2024 | |||
| Valuation | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.91M | |||
| Enterprise Value | 4.21M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.88 | |||
| Earnings Per Share Growth | -22.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 9.94 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.33 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -0.30 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.93M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 917 533 1469 | |||
| Address | 259 Liberty Avenue Staten Island, NY 10305 | |||
| Website | www.acurxpharma.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -152.41% | |||
| Return on Equity | -- | |||
| Income Statement | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -14.10M | |||
| Net Income (TTM) | -14.10M | |||
| Net Income Avl. to Common (TTM) | -14.10M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 45.61% | |||
| EPS Diluted (TTM) | -0.88 | |||
| EPS Diluted Growth (Q YOY) | 55.53% | |||
| Balance Sheet | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.71M | |||
| Cash Per Share (Q) | $0.22 | |||
| Total Current Assets (Q) | 3.86M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 615.10K | |||
| Current Ratio (Q) | 1.190 | |||
| Book Value Per Share (Q) | $0.04 | |||
| Total Assets (Q) | 3.86M | |||
| Total Current Liabilities (Q) | 3.24M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 3.24M | |||
| Total Common Equity (Q) | 615.10K | |||
| Cash Flow | ACXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 6.62M | |||
| Net Change in Cash (TTM) | -3.77M | |||
| Levered Free Cash Flow (TTM) | -2.56M | |||
| Cash from Operations (TTM) | -10.38M | |||
